Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Nebivolol
Drug ID BADD_D01541
Description Nebivolol is a racemic mixture of 2 enantiomers where one is a beta adrenergic antagonist and the other acts as a cardiac stimulant without beta adrenergic activity.[A182579] Treatment with nebivolol leads to a greater decrease in systolic and diastolic blood pressure than [atenolol], [propranolol], or [pindolol].[A182579] Nebivolol and other beta blockers are generally not first line therapies as many patients are first treated with thiazide diuretics.[A182594] Nebivolol was granted FDA approval on 17 December 2007.[L7985]
Indications and Usage Nebivolol is indicated to treat hypertension.[A2762,A182579,L7985,L7988]
Marketing Status approved; investigational
ATC Code C07AB12
DrugBank ID DB04861
KEGG ID D05127
MeSH ID D000068577
PubChem ID 71301
TTD Drug ID D0Z1UA
NDC Product Code 13668-356; 31722-586; 51407-486; 62559-276; 13668-354; 51407-483; 59651-137; 62559-278; 0904-7226; 62559-275; 63629-9589; 70756-025; 71209-058; 72241-033; 72241-034; 72241-035; 62559-277; 0904-7189; 70756-291; 71209-059; 13668-355; 31722-587; 43547-527; 50090-5708; 50090-5761; 50090-5775; 59651-140; 63629-9423; 63629-9424; 70756-292; 27241-182; 51407-485; 59651-139; 67877-391; 67877-392; 67877-393; 70518-3527; 71209-060; 72241-032; 65977-0048; 60687-641; 60687-652; 67877-390; 70756-293; 0904-7190; 0904-7225; 27241-179; 27241-180; 31722-585; 43547-524; 43547-525; 51407-484; 71209-061; 13668-353; 27241-181; 31722-588; 50090-5752; 59651-138
UNII 030Y90569U
Synonyms Nebivolol | Alpha,Alpha'-(Iminobis(Methylene))bis(6-Fluoro-3,4-dihydro)-2H-1-benzopyran-2-methanol | Bystolic | Nebilet | Silostar | Nebivolol Hydrochloride | Hydrochloride, Nebivolol | R 67555 | 67555, R | R-67555 | R67555 | Lobivon
Chemical Information
Molecular Formula C22H25F2NO4
CAS Registry Number 99200-09-6
SMILES C1CC2=C(C=CC(=C2)F)OC1C(CNCC(C3CCC4=C(O3)C=CC(=C4)F)O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Peripheral ischaemia24.04.03.002--
Platelet count decreased13.01.04.001--
Pruritus23.03.12.0010.000974%
Psoriasis23.03.14.002; 10.02.01.036--Not Available
Rash23.03.13.0010.001811%Not Available
Raynaud's phenomenon24.04.03.003--Not Available
Renal failure20.01.03.0050.000229%Not Available
Seizure17.12.03.0010.000115%
Shock24.06.02.002--Not Available
Skin discolouration23.03.03.0050.000390%Not Available
Skin disorder23.03.03.007--Not Available
Somnolence17.02.04.006; 19.02.05.003--
Syncope02.11.04.015; 24.06.02.012; 17.02.04.0080.000252%
Therapeutic response unexpected08.06.01.0010.000252%Not Available
Thrombocytopenia01.08.01.002--Not Available
Tinnitus04.04.01.002; 17.04.07.0040.000390%
Urticaria23.04.02.001; 10.01.06.0010.000585%
Vertigo17.02.12.002; 04.04.01.003--
Vision blurred06.02.06.007; 17.17.01.0100.000252%
Vomiting07.01.07.003--
Acute coronary syndrome24.04.04.011; 02.02.02.015--Not Available
Cardiac disorder02.11.01.003--Not Available
Malnutrition14.03.02.004--Not Available
Mental disorder19.07.01.002--Not Available
Erectile dysfunction21.03.01.007; 19.08.04.0010.000585%
Acute kidney injury20.01.03.0160.000115%
Therapy non-responder08.06.01.0630.000115%Not Available
The 3th Page    First    Pre   3    Total 3 Pages